FDA-CMS Parallel Review: A Failed Attempt at Spurring Innovation

In the United States today, it takes an average of $94 million and 54 months—about four-and-a-half years—for certain new medical devices to clear regulatory hurdles and become available for patients. The Food and Drug Administration (FDA) must approve medical devices, and the Centers for Medicare and Medicaid Services (CMS) must clear those devices for Medicare reimbursement. In Europe, the process takes just 11 months.

In 2010 the Food and Drug Administration and the Centers for Medicare & Medicaid Services (CMS) founded a pilot program for medical devices: simultaneous review of FDA premarket approval submissions and CMS national coverage determinations. By reducing the amount of time between obtaining marketing approval and securing Medicare coverage, the parallel-review program is supposed to facilitate the development of innovative medical devices and to shorten the time it takes to bring these devices to patients. After five years, however, the program’s impact remains limited: so far, only one device has been approved through this process. Why are manufacturers not more interested in this opportunity? While parallel review might shorten time to national coverage determination, it is likely to delay marketing of the device. Moreover, while meant to promote innovation, parallel review does not address key obstacles manufacturers currently encounter in bringing their products to market

Click here to read the full publication →